journal
MENU ▼
Read by QxMD icon Read
search

Current Hematologic Malignancy Reports

journal
https://www.readbyqxmd.com/read/30008035/reduced-intensity-conditioning-allogeneic-hematopoietic-stem-cell-transplantation-for-acute-lymphoblastic-leukemia-current-evidence-and-improving-outcomes-going-forward
#1
REVIEW
Jessica T Leonard, Brandon Hayes-Lattin
PURPOSE OF REVIEW: Outcomes for older adults with acute lymphoblastic leukemia (ALL) remain poor, and allogeneic hematopoietic stem cell transplant (HSCT) remains a potentially curative modality. However, benefits are offset by high rates of non-relapse mortality (NRM) in patients undergoing myeloablative conditioning (MAC) regimens. Reduced intensity conditioning (RIC) regimens can extend this therapy to adults who are unfit for MAC, although at the cost of higher relapse rates. In this review, we discuss evidence to support the usage of RIC regimens, controversies, and potential strategies to improve transplant outcomes going forward...
July 14, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29982866/economic-impact-of-oral-therapies-for-chronic-lymphocytic-leukemia-the-burden-of-novelty
#2
REVIEW
Talal Hilal, Jeffrey A Betcher, Jose F Leis
PURPOSE OF REVIEW: Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. RECENT FINDINGS: The cost of therapy for CLL has increased substantially since the introduction of oral therapies...
July 7, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29982865/shutting-down-acute-myeloid-leukemia-and-myelodysplastic-syndrome-with-bcl-2-family-protein-inhibition
#3
REVIEW
Prashant Sharma, Daniel A Pollyea
PURPOSE OF REVIEW: Apoptosis results from the interaction between pro- and anti-apoptotic proteins, mediated by BCL-2 homology 3 (BH3) proteins. B cell lymphoma-2 (BCL-2) is an inhibitor of apoptosis which stabilizes the mitochondria, resulting in the prevention of activation of the pro-apoptotic proteins. In addition, BCL-2 is overexpressed in the leukemic stem cell (LSC) population, and its inhibition may lead to selective LSC eradication. Herein, we will discuss the mechanism and rationale of BCL-2 inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an overview of the selective BCL-2 inhibitor venetoclax...
July 7, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29951889/molecular-insights-into-pathogenesis-of-peripheral-t-cell-lymphoma-a-review
#4
REVIEW
Waseem Lone, Aisha Alkhiniji, Jayadev Manikkam Umakanthan, Javeed Iqbal
PURPOSE OF REVIEW: Peripheral T cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative neoplasms, with at least 29 distinct entities described in current WHO classification. Using present diagnostic approaches, more than a third of PTCL cases cannot be classified, hence designated as PTCL-not otherwise specified (PTCL-NOS). Herein, we summarize the current genomic findings and their role in the molecular pathogenesis in different PTCL entities. RECENT FINDINGS: Gene expression profiling (GEP) studies have identified distinct molecular signatures for accurate diagnosis and elucidated oncogenic pathways enriched in major PTCL entities...
June 27, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29951888/updates-in-the-pathology-of-precursor-lymphoid-neoplasms-in-the-revised-fourth-edition-of-the-who-classification-of-tumors-of-hematopoietic-and-lymphoid-tissues
#5
REVIEW
Christopher Wenzinger, Eli Williams, Alejandro A Gru
PURPOSE OF REVIEW: Acute lymphoblastic leukemias (ALL) are malignant disorders of immature B or T cells that occur characteristically in children, usually under the age of 6 (75%). Approximately 6000 new cases of ALL are diagnosed each year in the USA, 80-85% of which represent B-ALL forms. Most presentations of B-ALL are leukemic, whereas T-ALL presents with a mediastinal mass, with or without leukemic involvement. The revised fourth edition of the World Health Organization (WHO) classification (2017) has introduced some changes in both B and T-ALL...
June 27, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29934935/disordered-immune-regulation-and-its-therapeutic-targeting-in-myelodysplastic-syndromes
#6
REVIEW
Kathryn S Ivy, P Brent Ferrell
PURPOSE OF REVIEW: Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein, we will summarize some of these findings and discuss the therapeutic strategies currently in development. RECENT FINDINGS: Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling...
June 22, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29948644/recent-advances-in-the-biology-and-treatment-of-t-cell-acute-lymphoblastic-leukemia
#7
REVIEW
Mehrdad Hefazi, Mark R Litzow
PURPOSE OF REVIEW: This article provides an overview of the current knowledge regarding the biology and treatment of T cell acute lymphoblastic leukemia (T-ALL) and highlights the most recent findings in this field over the past 5 years. RECENT FINDINGS: Remarkable progress has been made in the genomic landscape of T-ALL over the past few years. The discovery of activating mutations of NOTCH1 and FBXW7 in a majority of patients has been a seminal observation, with several early phase clinical trials currently exploring these as potential therapeutic targets...
June 15, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29943210/pathogenesis-of-enteropathy-associated-t-cell-lymphoma
#8
REVIEW
Udit Chander, Rebecca J Leeman-Neill, Govind Bhagat
PURPOSE OF REVIEW: To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs). RECENT FINDINGS: EATL frequently evolves from RCD type II (RCD II) but can occur "de novo" in individuals with celiac disease. Recurrent activating mutations in members of the JAK/STAT pathway have been recently described in EATL and RCD II, which suggests deregulation of cytokine signaling to be an early event in lymphomagenesis...
June 15, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29730710/frailty-in-hematologic-malignancy
#9
REVIEW
Thuy T Koll, Ashley E Rosko
PURPOSE OF REVIEW: Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS: Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic...
May 5, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29713873/post-et-and-post-pv-myelofibrosis-updates-on-a-distinct-prognosis-from-primary-myelofibrosis
#10
REVIEW
Francesco Passamonti, Barbara Mora, Daniela Barraco, Margherita Maffioli
PURPOSE OF REVIEW: The purpose of this review is to help doctors in the management of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) facing diagnostic criteria, prognostication, and treatment possibilities. RECENT FINDINGS: Diagnostic criteria of primary myelofibrosis (PMF) have been recently updated from the WHO classification. A clear-cut distinction between pre-fibrotic and overt PMF has been done. Concerning PPV and PET MF, the criteria come from 2008...
April 30, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29705880/the-effect-of-psychosocial-interventions-on-outcomes-for-caregivers-of-hematopoietic-cell-transplant-patients
#11
REVIEW
Lauren R Bangerter, Joan M Griffin, Shelby Langer, Bashar Hasan, Wonsun Sunny Kim, M Hassan Murad, Nandita Khera
PURPOSE OF REVIEW: Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematically evaluates psychosocial interventions for caregivers of HCT patients. RECENT FINDINGS: The search yielded 12 studies (7 efficacy and 5 feasibility studies) enrolling 931 caregivers...
April 28, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29951831/novel-approaches-for-the-management-of-al-amyloidosis
#12
REVIEW
Nisha S Joseph, Jonathan L Kaufman
PURPOSE OF REVIEW: Light-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent strides in more accurate diagnosis and effective treatment. Here, we discuss the most recent updates and advancements during the past year in the diagnosis, prognostication, and management of AL amyloidosis both in the upfront and relapsed setting. RECENT FINDINGS: New imaging modalities, such as cardiac magnetic resonance (CMR) and use of fluorine-labeled radiotracers, are emerging as an important diagnostic tool in conjunction with biomarkers in the diagnosis, prognosis, and monitoring of the effects of therapy...
June 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29796726/management-of-myelofibrosis-related-cytopenias
#13
REVIEW
Prithviraj Bose, Srdan Verstovsek
PURPOSE OF REVIEW: Cytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest efficacy and ruxolitinib, the only approved drug for myelofibrosis, is myelosuppressive. Yet, dose optimization of ruxolitinib is important for its survival benefit in patients with advanced disease. We sought to summarize the data on treatments for cytopenias available at present and review promising agents in development and emerging strategies...
June 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29725932/light-chain-cast-nephropathy-practical-considerations-in-the-management-of-myeloma-kidney-what-we-know-and-what-the-future-may-hold
#14
REVIEW
Sandhya Manohar, Samih H Nasr, Nelson Leung
PURPOSE OF REVIEW: To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event. RECENT FINDINGS: The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN...
June 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29687320/tyrosine-kinase-inhibitors-in-the-treatment-of-chronic-phase-cml-strategies-for-frontline-decision-making
#15
REVIEW
James A Kennedy, Gabriela Hobbs
PURPOSE OF REVIEW: Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challenging. Here we will review recent advances that help inform the selection of a first-line TKI. RECENT FINDINGS: Extended follow-up of the seminal CML trials has demonstrated the long-term efficacy of TKIs, while also highlighting significant differences in their respective toxicity profiles and potency...
June 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29680938/diagnosis-and-novel-approaches-to-the-treatment-of-hypereosinophilic-syndromes
#16
REVIEW
Melanie C Dispenza, Bruce S Bochner
PURPOSE OF REVIEW: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. RECENT FINDINGS: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib...
June 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29667156/how-we-manage-patients-with-plasmacytomas
#17
REVIEW
Despina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
PURPOSE OF REVIEW: To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM). RECENT FINDINGS: Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci...
April 17, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29644531/splanchnic-vein-thrombosis-in-the-myeloproliferative-neoplasms
#18
REVIEW
Imo J Akpan, Brady Lee Stein
PURPOSE OF REVIEW: To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis. RECENT FINDINGS: The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women...
April 11, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29516333/update-on-the-treatment-of-anaplastic-large-cell-lymphoma
#19
REVIEW
Khoan Vu, Weiyun Ai
PURPOSE OF REVIEW: Given the rarity of anaplastic large cell lymphoma (ALCL), studies evaluating new therapies have typically grouped ALCL together with other peripheral T cell lymphomas (PTCL). Thus, the treatment paradigm for ALCL largely mirrors that of PTCL in general. In this review, we discuss the current standard of care as well as emerging therapies, including antibody-based drugs, in systemic ALCL as well as primary cutaneous and breast implant-associated ALCL. RECENT FINDINGS: High CD30 expression in ALCL has allowed the use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in both systemic and primary cutaneous ALCL...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29484578/value-based-care-in-hematopoietic-cell-transplantation-and-cellular-therapy-challenges-and-opportunities
#20
REVIEW
Gunjan L Shah, Navneet Majhail, Nandita Khera, Sergio Giralt
PURPOSE OF REVIEW: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system...
April 2018: Current Hematologic Malignancy Reports
journal
journal
41232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"